📖
LncRNA MYO16-AS1 and MICAL2 axis sustains proliferation and migration in ovarian cancer cells and unveils a therapeutic vulnerability in patient-derived tumor organoids
Mohammad Ahmad, L. Thorel, E. Brotin, E. Abeilard, M. N'Diaye, Shéhérazade Sebda, Jean-Pascal Meneboo, Martin Figeac, B. Bernay, L. Poulain, L. B. Weiswald, C. Denoyelle, Matthieu Meryet-Figuière

LncRNA MYO16-AS1 and MICAL2 axis sustains proliferation and migration in ovarian cancer cells and unveils a therapeutic vulnerability in patient-derived tumor organoids

Science & Mathematics Published 2025 Verification Pending

Overview & Synopsis

Ovarian carcinoma (OC) exhibits a 5-year survival rate of below 40 %, mainly due to late-stage diagnosis and recurrence associated to resistance to chemotherapy. Long noncoding RNAs (lncRNAs) are involved in numerous cellular processes of critical physiological relevance and dysregulation of their expression has been implicated in various pathologies, including cancer. However, the functions and mechanisms of the majority of them remains largely uncharacterized. To investigate their potential roles in treatment response, we performed RNA sequencing (RNA-Seq) on 47 High Grade Serous Ovarian Carcinoma (HGSOC) samples, including 28 from patients who achieved a complete response to first-line therapy and 19 from those with partial response or stable disease. Among the differentially expressed transcripts, we identified MYO16-AS1, a poorly characterized lncRNA, whose overexpression correlated with decreased overall survival (OS) in OC. Functional assays revealed that MYO16-AS1 downregulation significantly impairs proliferation, migration and invasion in SKOV3 ovarian cancer cell line. Integrative transcriptomic and proteomic analyses further demonstrated that MYO16-AS1 regulates a network of genes associated with these oncogenic processes. Notably, we identified MICAL2 as a key downstream effector, whose downregulation induces similar consequences observed upon MYO16-AS1 downregulation, suggesting that MICAL2 is a major mediator of the functional effect of MYO16-AS1 in OC. Strikingly, MICAL2 inhibition markedly reduced proliferation accross several OC patient-derived tumor organoid models, regardless of their response to chemotherapy, thereby underscoring MICAL2 as a promising therapeutic target in OC.

Indexed from repository: HAL Open Science (hal.science)
Loading document from verified source...
Keyboard Shortcuts: ← / → for pages • + / - for zoom • 0 to fit width Powered by Mozilla PDF.js v3.11

Document Information

Document Title LncRNA MYO16-AS1 and MICAL2 axis sustains proliferation and migration in ovarian cancer cells and unveils a therapeutic vulnerability in patient-derived tumor organoids
Author / Organization Mohammad Ahmad, L. Thorel, E. Brotin, E. Abeilard, M. N'Diaye, Shéhérazade Sebda, Jean-Pascal Meneboo, Martin Figeac, B. Bernay, L. Poulain, L. B. Weiswald, C. Denoyelle, Matthieu Meryet-Figuière
Subject & Discipline Multidisciplinary Academic Open Research
Categories Science & Mathematics
Publication Year 2025
License / Rights Open Access / Creative Commons
Resource Verification Listed PDF (Verification Pending)
Original Host Website HAL Open Science (hal.science)
File Format application/pdf (Portable Document Format)
Language EN
Catalog ID DOC-164795
Original Source Link Visit Source Page on hal.science »